Frequent hepatitis B surface antigen ( HBsAg) clearance during tenofovir therapy in persons with HIV /hepatitis B virus coinfection

Documenti analoghi

• Kinetics of the hepatitis B core‐related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide
  di: Norio Itokawa, et al.
  Pubblicazione: (2024)
• Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B
  di: Mina S. Farag, et al.
  Pubblicazione: (2024)
• CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
  di: Hye Won Lee, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV
  di: Paul Thoueille, et al.
  Pubblicazione: (2024)
• Do people with HIV really have the choice between oral and injectable ART ? Evidence from a multicentric survey in the Swiss HIV cohort study
  di: Yonas Martin, et al.
  Pubblicazione: (2026)